Menopause hormone therapy is everywhere right now, and we sort science from hype using the newest ACP and ACOG guidance. We explain why the treatment is often simpler than social media claims, and how to spot hormone grift without dismissing real symptoms.

• menopause hype and the rise of cash-pay menopause clinics
• the medical hype cycle and how WHI shaped fear and overcorrection
• ACP guideline: estrogen with progestogen first line for vasomotor symptoms when a uterus is present
• nonhormonal options and where SSRIs, SNRIs, gabapentin, and neurokinin receptor antagonists fit
• route myths: why transdermal is not proven “safer” than oral for rare harms
• ACOG guidance on vasomotor symptoms, sleep disturbance, mood symptoms, timing of initiation, and contraindications
• perimenopause management: contraception-based ovarian suppression versus MHT supplementation
• why routine hormone testing, AMH, saliva, urine, and dried urine panels do not guide care
• testosterone reality check: limited indications, superphysiologic dosing, and potential cardiovascular risk
• four red flags for social media hormone grifters: broad cure-all claims, hormone testing products, compounded hormones and pellets, excessive testosterone

Be sure to check out thinking about obgyn.com for more information, and be sure to follow us on Instagram.

0:01 Why Menopause Is Everywhere

5:54 The Hype Cycle Behind Hormones

11:12 ACP Guideline First Line Treatment

14:41 Transdermal Versus Oral Risk Claims

17:54 ACOG Vasomotor Sleep Mood Guidance

26:46 Perimenopause Toolkit And Lab Testing

32:05 Testosterone Risks And Overuse

34:19 Four Red Flags For Hormone Grifters

Follow us on Instagram @thinkingaboutobgyn.

We dig into how good stories and elegant mechanisms can seduce clinicians into using fertility and surgical “add-ons” long before the evidence is ready. We also connect policy, access, and misinformation to a disturbing rise in ectopic pregnancy deaths, then end with what better studies should look like when patient safety is on the line.

• why low-dose naltrexone becomes a fertility add-on despite unclear mechanisms
• biologic plausibility versus proof, and why theory cannot replace trials
• what the available LDN data looks like, including weak endpoints and missing live birth outcomes
• practice inertia, file drawer bias, and when a therapy belongs in routine care
• ProPublica’s ectopic pregnancy mortality signal and how to interpret CDC WONDER data
• COVID-era care disruptions, hospital closures, and delayed early pregnancy evaluation
• Dobbs-era legal ambiguity, chilling effects, and implications for methotrexate timing
• a new Nature Medicine finding on ISM2 as an early biomarker for preeclampsia and fetal growth restriction
• V-NOTES versus vaginal hysterectomy trial design problems, including power, exclusions, and comparators
• conflicts of interest, blinding failures, and how low-quality studies pollute meta-analyses
Everybody remember to get your ABOG stuff done in the next month or so.

Be sure to check out thinkingaboutobgyn.com for more information and be sure to follow us on Instagram.

0:34 Low-Dose Naltrexone For Fertility

8:38 Evidence Gaps And Practice Inertia

17:14 Ectopic Pregnancy Deaths Are Rising

22:00 Access Problems And Social Media Misinformation

24:15 Abortion Bans And Delayed Ectopic Care

29:32 ISM2 Biomarker For Preeclampsia Risk

32:31 V-Notes Versus Vaginal Hysterectomy Study

41:40 Power, Outcomes, And Unfair Comparisons

47:50 Conflict Of Interest And Broken Blinding

55:09 Where V-Notes Came From

1:01:31 Skills, Tradeoffs, And Final Reminders

Follow us on Instagram @thinkingaboutobgyn.